Tango Therapeutics, a clinical-stage biotechnology company, has recently announced an important milestone in their research. The first patient has been dosed in the phase 1/2 trial of TNG462, a potential treatment for patients with MTAP-deleted solid tumors. This trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and efficacy of TNG462. Notably, the drug has received Fast Track designation from the FDA due to its potential to address an unmet medical need. Tango Therapeutics is committed to developing innovative therapies specifically designed for patients with MTAP-deleted cancers.
In addition to TNG462, Tango Therapeutics is also investigating another promising treatment option called TNG908. This drug is a brain-penetrant PRMT5 inhibitor that works in conjunction with MTA-cooperative mechanisms. By advancing both programs simultaneously, Tango hopes to have a broader impact on various indications and offer more therapeutic choices for patients.
Both TNG908 and TNG462 are powerful PRMT5 inhibitors that selectively target cancer cells with MTAP deletion while preserving normal cells. Preclinical studies have demonstrated